Cypress Bioscience Inc Watch

from 10-Q 38 pages Asset Purchase Agreement by and Between Cypress Bioscience, Inc. and Marina Biotech, Inc. Dated as of August 25, 2010 I

from 10-Q 49 pages License & Development Agreement

from 10-Q 3 pages Letter Agreement

from 10-Q 58 pages Amended and Restated License Agreement

from 8-K 2 pages Executive Bonuses 2010 the 2010 Corporate Objectives That Could Trigger Bonus Payments Under the 2010 Bonus Plan Are: 1. Transition Toward Profitability in Commercial Operations 2. Accumulate a Portfolio of Strategic Assets 3. Increase Stockholder Value

from 10-K 2 pages Fourth Amendment

from 10-K 3 pages Second Amendment to Lease

from 10-K 2 pages Amendment to Amended and Restated Employment Agreement

from 10-K 7 pages Cypress Bioscience, Inc. 2009 Equity Incentive Plan [Form] Restricted Stock Unit Agreement

from 8-K 2 pages Executive Bonuses 2009 There Are Two 2009 Corporate Objectives That Could Trigger Bonus Payments Under the 2009 Bonus Plan: 1) Complete a Major Corporate Event, Such as an In-License or Product Acquisition (50%) 2) Achieve Commercial Objectives Established for Savella and the Avise Product Line

from 10-K 18 pages Amended and Restated Employment Agreement Agreement

from 10-K 23 pages Cypress Bioscience, Inc. Amended and Restated Severance Benefit Plan

from 10-K 22 pages Amended and Restated Employment Agreement Agreement

from 8-K 11 pages Retention Agreement

from 8-K 9 pages Non-Competition Agreement

from 8-K 16 pages Employment Agreement by and Between Cypress Bioscience, Inc. and Michael J. Walsh Employment Agreement

from 8-K 2 pages Specific Weighting Percentages Are Assigned to Each of the Objectives – These Are Noted in Parenthetical After Each Objective. the Bonus Payable Is Equal to the Weighting Percentage Multiplied by the ‘Target Bonus’ Amount as Defined Below. the Bonus Is Payable Upon Achievement of Either Objective. Note That Whether or Not a Particular Transaction Qualifies as a ‘Major Corporate Event’ Is Left to the Discretion of the Compensation Committee. Payments Under the 2008 Bonus Plan, if Any, Are Contingent Upon the Company’s Achievement of Certain Corporate Objectives Described Above, and the Relevant Officers’ Continued Employment With the Company on the Date of Payment. the ‘Target Bonus’ Amounts Are Defined As: For Srinivas Rao, Mike Gendreau, Denise Wheeler: 25% X Annual Base Salary*

from 8-K ~1 page Amendment to the Amended and Restated Employment Agreement

from 10-Q 7 pages First Amendment

from 8-K 2 pages Executive Bonuses 2007 A. There Is a Primary 2007 Milnacipran Related Corporate Objective: 1. Statistical Significance Achieved on MD-02, Milnacipran Phase III Trial. (100%) a 100% Weighting Percentage Is Assigned to This Objective. the Bonus Payable Is Equal to the Weighting Percentage Multiplied by the ‘Target Bonus’ Amount as Defined Below. the Bonus Is Payable Upon Achievement of the Objective (Top-Line Data Announcement). B. in Addition, the 2007 Annual Corporate Objectives Include: 1. Major Corporate Event, Such as an In-License or Product Acquisition. (70%) 2. Increase Shareholder Value (Defined as an Increase in Stock Price of 50% or More Versus 12-31-06 Close on Average for 20 Consecutive Trading Days as Well as Closing Price on 12-31-07). (30%)